Risk of Secondary AML/MDS in CLL vs Multiple Myeloma
Patients with CLL treated with chemoimmunotherapy have a modest but real risk of developing therapy-related MDS/AML, with incidence rates of 1-3% after fludarabine-based regimens, particularly FCR (fludarabine, cyclophosphamide, rituximab), while bendamustine-rituximab (BR) carries a lower risk at approximately 1%. 1
Risk Stratification by Treatment Regimen in CLL
FCR-Associated Risk
- FCR therapy carries a 3% incidence of secondary AML/MDS after median follow-up of 58 months 1
- The risk is particularly elevated when fludarabine (a purine analogue) is combined with alkylating agents like cyclophosphamide 2
- Median latency period from FCR completion to t-MDS/AML diagnosis: 41 months (range 7-56 months) 3
BR-Associated Risk
- BR demonstrates significantly lower risk at 1% incidence of secondary AML/MDS 1
- This represents a two-thirds reduction in risk compared to FCR
- BR should be strongly considered for elderly or previously infected patients where this risk reduction matters 1
Mechanism of Leukemogenesis
The pathogenesis involves:
- Alkylating agents (cyclophosphamide, chlorambucil) - associated with 5q/7q abnormalities, latency 5-7 years 2
- Purine analogues (fludarabine) - particularly dangerous when combined with alkylators 2
- Topoisomerase II inhibitors - shorter latency (2-3 years), associated with 11q23/21q22 translocations 2
Prognosis of CLL-Associated t-MDS/AML
The prognosis is dismal with median survival of only 4-6 months after t-MDS/AML diagnosis 4, 3, 5:
- 78-82% have complex/high-risk cytogenetics, including chromosome 5/7 abnormalities 4, 5
- Disease course is generally progressive and more resistant to conventional cytotoxic therapies than de novo MDS/AML 2
- Median overall survival: 6.3 months (95% CI 4.0-8.7) 5
- Importantly, history of CLL does not independently worsen prognosis beyond the IPSS-R score - the poor outcomes are driven by the adverse cytogenetics, not the CLL history itself 4
Multiple Myeloma Comparison
Multiple myeloma patients face a HIGHER absolute risk of t-MDS/AML compared to CLL patients, though the outcomes are similarly poor 5:
MM-Associated Risk Profile
- Median interval from MM diagnosis to t-MN: 7 years (95% CI 5.0-28.0) 5
- Distribution: 70% develop t-MDS, 23% t-AML, 6% t-CMML 5
- 78-82% have complex/high-risk cytogenetics 5
- Median OS after t-MN diagnosis: 6.3 months (95% CI 4.0-8.7) - essentially identical to CLL 5
Contributing Factors in MM
- Prolonged exposure to alkylating agents (melphalan)
- Autologous stem cell transplantation with high-dose chemotherapy (42.6% of patients) 5
- Novel agents (lenalidomide, thalidomide, bortezomib) - risk profile still being defined 5
- Cumulative cytotoxic burden from multiple treatment lines
Clinical Implications and Monitoring
Treatment Selection Strategy
When choosing first-line CLL therapy, weigh the 3% vs 1% t-MDS/AML risk (FCR vs BR) against efficacy differences:
- FCR produces higher CR rates (40% vs 31%) and longer PFS (55.2 vs 41.7 months) 1
- For patients >65 years or with infection history, BR is preferred due to lower infection rates AND lower t-MDS/AML risk 1
- For fit patients <65 years with mutated IGHV, FCR remains standard despite the higher secondary malignancy risk 1
Common Pitfall
Do not assume all secondary AML in CLL is therapy-related - rare cases of concurrent de novo AML and CLL exist (<1%), representing separate clonal processes with distinct cytogenetics 6. However, after fludarabine-based therapy, the presumption should be therapy-related disease.
Surveillance Considerations
- No specific screening recommendations exist for asymptomatic patients
- Maintain high clinical suspicion for new cytopenias, particularly 3-7 years post-alkylator therapy
- Complex karyotype at t-MDS/AML diagnosis portends extremely poor prognosis regardless of primary malignancy 4, 5